Inhibitors of the p53/hdm2 protein–protein interaction—path to the clinic  by Carry, Jean-Christophe & Garcia-Echeverria, Carlos
Bioorganic & Medicinal Chemistry Letters 23 (2013) 2480–2485Contents lists available at SciVerse ScienceDirect
Bioorganic & Medicinal Chemistry Letters
journal homepage: www.elsevier .com/ locate/bmclBMCL DigestInhibitors of the p53/hdm2 protein–protein interaction—path
to the clinic0960-894X  2013 Elsevier Ltd.
http://dx.doi.org/10.1016/j.bmcl.2013.03.034
⇑ Corresponding author. Fax: +33 1 58933471.
E-mail address: carlos.garcia-echeverria@sanoﬁ.com (C. Garcia-Echeverria).
Open access under CC BY-NC-ND license.Jean-Christophe Carry, Carlos Garcia-Echeverria ⇑
Oncology Drug Discovery and Preclinical Development, Sanoﬁ, 13 Quai Jules Guesde, 94400 Vitry-sur-Seine, Francea r t i c l e i n f o
Article history:
Received 25 November 2012
Revised 1 March 2013
Accepted 7 March 2013
Available online 16 March 2013
Keywords:
p53
hdm2
hdmx
Protein–protein interaction
Anticancer agenta b s t r a c t
A growing number of the elements identiﬁed in intracellular signaling events that affect cell growth and
transformation are proteins that physically interact with each other via domains or speciﬁcally recog-
nized amino acid sequences. Some of these intracellular protein–protein interactions are attractive tar-
gets for anticancer targeted therapy, but progress in this ﬁeld has been compromised by the paucity of
compounds with suitable biological proﬁles and pharmacological properties. This Letter covers salient
achievements in the identiﬁcation and development of inhibitors of the p53–hdm2 protein–protein inter-
action, and highlights different screening techniques and structure-based design approaches that may be
brought to bear on the discovery and development of inhibitors of other therapeutically relevant intra-
cellular protein–protein interactions.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.The p53 protein, also known as the guardian of the human gen-
ome, is a transcription factor that controls the cellular response to
DNA damage or other stress stimuli through the induction of cell-
cycle arrest, DNA repair, apoptosis or senescence.1 These responses
guard against ampliﬁcation or replication of genetic alterations
within a population of cells. Among the known mechanisms by
which the tumor suppressor function of p53 is regulated, signiﬁ-
cant drug discovery efforts have been directed to block the interac-
tion of p53 with hdm2 (also known as mdm2, mouse double
minute 2 homolog), which is an E3 ubiquitin ligase that targets
p53 for degradation by the proteasome pathway.2 Not surprisingly,
there is an increased frequency of ampliﬁcation of the MDM2 gene
in human cancer cells as an effective mechanism to block tumor
cell death. The disruption of the p53/hdm2 protein–protein inter-
action (PPI) is therefore an attractive approach for targeted anti-
cancer therapy because it provides the possibility to activate the
p53 responsive reporter genes in malignant cells containing
wild-type p53 (Fig. 1).3 As for other members of this family of ther-
apeutic targets, the p53/hdm2 PPI originally proved resistant to
pharmaceutical intervention, and for a while the possibility of
identifying and developing inhibitors of this PPI was doubted. This
Letter covers salient achievements in the identiﬁcation and devel-
opment of such compounds, and highlights different screening
techniques and structure-based design approaches that have been
exploited to identify mechanism-based tool compounds and thecurrent clinical candidates (for recent review papers on this topic,
see Ref. 4).
PPIs often span large surface areas (>1600 Å2) and, unlike en-
zyme/substrate contacts, they lack deep, well deﬁned binding
pockets. The X-ray structure of the N-terminal p53-[17–125] bind-
ing domain of hdm2 and its analog from Xenopus laevis bound to a
15-residue transactivation domain peptide of p53 shed light on the
structural features and amino acid side chains involved in this
intracellular PPI.5 The crystal structure revealed that the p53/
hdm2 edge buries a total of 1498 Å2 of surface area, 690 Å2 thereof
in hdm2. The interface relies on the steric complementary between
the hdm2 cleft and the hydrophobic face of the a-helix of p53, and
in particular on a triad of p53 amino acids. Thus, the side-chains of
Phe-19, Trp-23 and Leu-26 have extended conformations and pack
close to each other, making sequential and extensive van der Waals
contacts with the pockets of hdm2. These interactions are comple-
mented only by two intermolecular hydrogen bonds: one between
the Phe-19 backbone amide of p53 and the Gln-72 side-chain of
hdm2, and another between the nitrogen of p53 Trp-23 indole
group and the hdm2 Leu-54 backbone carbonyl moiety. The critical
roles of these residues in molecular recognition were further
demonstrated in experiments performed with phage display
peptide libraries.6 Screening of 12- and 15-mer phage display
libraries resulted in the identiﬁcation of a peptide –Ac-Met-
Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH2– that had
sub-lM afﬁnity for hdm2 (IC50 = 313 nM), and was 28-fold more
potent than the corresponding wild-type p53-derived peptide.
Truncation studies that included the synthesis and biological eval-
uation of all the 11, 10, 9 and 8-mer derived peptides revealed that
Figure 1. Schematic representation of the p53 pathway and its regulation by hdm2 or an inhibitor ([I]) of the p53/hdm2 protein–protein interaction.
J.-C. Carry, C. Garcia-Echeverria / Bioorg. Med. Chem. Lett. 23 (2013) 2480–2485 2481the octapeptide –H-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-NH2, IC50 =
8.9 lM—was the minimal sequence retaining micromolar activity
for hdm2. The iterative optimization of this recognition motif
resulted in the identiﬁcation of a peptide (Ac-Phe-Met-Aib-Pmp-
6-Cl-Trp-Glu-Ac3c-Leu-NH2) that inhibited full-length p53 binding
to GST-hdm2 with an IC50 value of 5 nM. During this study, a
substantial potency gain was obtained when chlorine was incorpo-
rated at the six position of the indole moiety of Trp. In accordance
with the molecular modeling prediction that motivated this
modiﬁcation, the X-ray structure of the modiﬁed peptide bound
to hdmx, which is an additional hdm2 family member, later
conﬁrmed that the 6-Cl-Trp residue protrudes into the Trp-23
binding site of hdmx and optimizes the steric complementarity
of the protein–peptide interface by establishing additional van
der Waals contacts at the bottom of the pocket.7 Although the
initial appeal of polypeptides to target p53/hdm2 was limited
due to their poor membrane permeability and physiological stabil-
ity, the pharmacophore model that emerged from the preceding
work has been extensively and successfully exploited in the iden-
tiﬁcation of non-peptidic and peptide-like inhibitors for this target.
High-throughput data-generation techniques have been exten-
sively used to identify hit candidates for this PPI. One of the early
bioassay-based high-throughput screening (HTS) campaigns
entailed the use of the so-called ThermoFluor method. This ap-
proach exploits ﬂuorescent dyes tomonitor thermal protein unfold-
ing, allowing the detection of test compounds binding to target
protein. Hdm2 screening of around 338,000 compounds provided
1216 hits, of which 116 originated from a benzodiazepinedione li-
brary (e.g., compound 1, racemic mixture; Fig. 2).8 A hit-to-lead
optimization program provided compounds with improved
in vitro inhibitory activity (compound 2, Fig. 2; Kd = 80 nM) and
established extensive structure–activity relationships (SARs),
including the importance of an S,S-absolute stereochemistry for bio-
logical activity. However, these compounds and derivatives thereof
(e.g., 1,4-thienodiazepine-2,5-diones, compound 3; Fig. 2)9 showed
systematically weak biological activity in cellular settings and did
not progress any further. Similar limitations and outcomehave been
reported for chalcones (e.g., compound 4, Fig. 2)10 and chromeno-
triazoloprimidine-based hdm2 inhibitors (e.g., compound 5,
Fig. 2).11
Imidazoline derivatives were also identiﬁed by HTS of libraries
of synthetic molecules, and subsequently optimized to afford com-
pounds 6, 7, and 8 (Fig. 2).12 These molecules, which are widely
known as nutlins to acknowledge that they were originally discov-ered in Nutley (New Jersey, USA), displaced p53 from its complex
with hdm2 with IC50 values in the 100–300 nM range. The hdm2
binding modes of these inhibitors have been determined by
X-ray crystallography and NMR. The cis-imidazoline scaffold repro-
duces features of the a-helical backbone of the p53 protein and di-
rects its three aryl groups to the critical binding pockets on hdm2.
Thus, the para-halogen-substituted phenyl moieties in positions 4
and 5 ﬁt into the Leu-26 and Trp-23 pockets, while the interactions
mediated by the side-chain of Phe-19 are partially mirrored by the
2-isopropyloxy phenyl synthon. In addition, the 4-methoxy func-
tionality mimics the aliphatic side-chain of Leu-22 in p53. Of spe-
cial note, these molecules are unable to recapitulate any of the two
hydrogen bond interactions observed in the X-ray structure of the
ligand-bound hdm2 protein. The compounds increase in a dose-
dependent manner the levels of hdm2, p53 and p21waf1 in tumor
cell lines with wild-type p53 (e.g., HCT116 and RKO) leading to cell
cycle arrest and apoptosis. Animal studies demonstrated that Nut-
lin-3 is effective in decreasing tumor growth in nude mice bearing
sc SJSA-1 tumor xenograft (200 mg/kg bid, per os) over a 20-day
period with no apparent toxicity. These early preclinical data sup-
ported the idea that pharmacological activation of p53 may have
useful antitumor activity and therapeutic window, and triggered
an increased interest for this therapeutic target. Additional preclin-
ical studies have shown that nutlins can synergize with a wide
variety of standard-of-care or targeted anticancer agents conﬁrm-
ing the potential development of p53/hdm2 inhibitors for use in
cancer therapy either as single agents or in combination with
chemotherapy.4b
The limited cellular activity and pharmacological properties of
nutlins prompted the preparation and biological evaluation of fur-
ther analogs.13 This optimization work led to the discovery of
RG7112 (RO5045337; compound 9, Fig. 2; Kd = 10.7 nM),14 which
was the ﬁrst p53/hdm2 inhibitor to enter clinical trials. RG7112
has been tested in patients (oral doses ranged between 20 and
1920 mg/m2/day for 10 days followed by 18 days of rest between
cycles) with advanced solid tumors (e.g., well-differentiated and
dedifferentiated liposarcomas) or hematological malignancies
(e.g., acute myelogeneous leukemia). Evidence of target engage-
ment at doses >320 mg/m2/day and clinical beneﬁts have been re-
cently reported.15 Of special note, is the measurement of MIC-1 in
blood samples as a surrogate pharmacodynamic read-out. This
protein is secreted in serum when p53 is activated and the use of
its blood level avoids the awkwardness of needing tumor biopsies
to demonstrate target modulation in clinical settings. The most
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Figure 2. Representative examples of p53/hdm2 inhibitors derived from hits identiﬁed by experimental screening.
2482 J.-C. Carry, C. Garcia-Echeverria / Bioorg. Med. Chem. Lett. 23 (2013) 2480–2485common and signiﬁcant adverse events reported upon administra-
tion of RG7112 to cancer patients have been so far neutropenia and
thrombocytopenia, which can be considered on-target and intrin-
sic to the mechanism-of-action for this p53/hdm2 agent. Another
p53/hdm2 inhibitor (RG7338, RO5503781) started Phase I clinical
trials at the end of 2011, but its structure has not been disclosed
yet.
Parallel to the p53/hdm2 PPI disruptors obtained by screening
proprietary compound collections, in silico and computational ap-
proaches have also been used by several groups to assist in the
search of hits for this target (for additional examples not covered
herein, see Ref. 16).
A long-standing goal of medicinal chemists has been to develop
approaches for the de novo design of inhibitors based on the
knowledge of a protein’s 3D-structure. In this context, molecular
modelling approaches have been able to identify novel p53/hdm2
leads that display the critical pharmacophores in a suitable
3D-spatial orientation for binding to the hdm2 cleft. Originally in-
spired by the presence of indole-mimics in natural products,4a
oxindole and isoindolinone derivatives were identiﬁed through
structure-based de novo design. In the case of the spiro(oxindole-
3,30-pyrrolidine) core structure (also known as spiro-oxindole), this
series has led to advanced lead compounds and ultimately to the
identiﬁcation of a clinical candidate. The starting point in thisstrategy was to mimic the van der Waals and hydrogen bond inter-
actions of the side-chain of Trp-23 and build the other interactions
once a suitable platform and efﬁcient synthetic approach (e.g.,
[1,3]-dipolar cycloaddition) had been developed.17 Consistent with
the initial design of this compound class, the X-ray structure of
hdm2 complexed with an spiro-oxindole analog (compound 10,
Fig. 3)18 has shown that the oxindole moiety inserts deeply into
the Trp-23 pocket and mirrors the putative p53 interactions with
hdm2. The 2-ﬂuoro-3-chlorophenyl ring binds to the Leu-26 bind-
ing-site and its plane is rotated to allow the phenyl substituent
atoms to reach the bottom of this hdm2 pocket. The neopentyl
chain ﬁlls the Phe-19 cleft and, interestingly, the establishment
of this contact requires a substantial induced-ﬁt. To this end, the
peptidic backbone of His-73 is retracted outward from the pocket
to allow the side-chain of Tyr-67 to rotate. Although the pyrroli-
dine amide carbonyl forms a short hydrogen bond with His 96,
the remaining part of the molecule, in particular the amide substi-
tuent was not visible in the electron density map indicating high
ﬂexibility and the lack of relevant direct interactions with the pro-
tein. It is important to mention that the stereochemical conﬁgura-
tion of compound 10 is different from other members of this series,
and the reported binding mode may not recapitulate the interac-
tions of other closely similar, but enantiomerically different
analogs.17
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Figure 3. Representative examples of p53/hdm2 inhibitors derived from designed scaffolds.
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late potency and ﬁne-tune pharmacological properties19 led to
the identiﬁcation of SAR299155 (compound 11, Fig. 3). The com-
pound binds to hdm2 with a Ki of 10 nM, displays high speciﬁcity
over other PPIs, and signiﬁcantly inhibits the proliferation of a
broad panel of wild-type p53 tumour cell lines (IC50 <100 nM). In
acute pharmacokinetic/pharmacodynamics preclinical in vivo
studies, the compound triggers a rapid and sustained target
engagement when administered orally to tumor bearing mice as
demonstrated by monitoring relevant biological read-outs such
as p53, p21waf1, hdm2 and PUMA. Tumour regression in multiple
models (e.g., sc SJSA-1 tumor or patient-derived liposarcoma xeno-
graft models) is achieved at tolerated doses when the compound is
administered orally on a daily or weekly schedule. The pharmaco-
logical, biological and preclinical safety proﬁles of SAR299155
supported its clinical development and this drug is currently
undergoing Phase I clinical trials in cancer patients.
The original spiro-oxindole scaffold has been further modiﬁed
and cyclohexenone/cyclohexanone20 and lactam20a,21 analogs have
been reported, as well as tetracyclic piperidine derivatives.22 Alter-
natively, simpliﬁed ‘open-ring’ derivatives23 devoid of the oxindole
moiety have also been reported. Finally, spiro(oxindole-3,30-thia-
zolidine)-based analogs of the spiro-oxindolepyrrolidine core have
been recently published.24
Structural–rational design has also led to the identiﬁcation of
the rigid piperidine scaffold and systemic optimization of this lead
series has resulted in the advancement of compounds with prom-
ising biological and pharmacological properties. A representative
example from the elegant medicinal chemistry optimization con-
ducted with the original piperidine hit is AM-8553 (compound
12, Fig. 3).25 This molecule blocks the p53/hdm2 PPI with a disso-
ciation constant Kd value of 0.4 nM, exhibits a dose-dependent
increase of p21waf1 mRNA in HCT116 p53 wild-type cells
(IC50 = 0.19 lM) and potently blocks the proliferation of this tumor
cell line (IC50 = 0.19 lM; 100-fold selectivity over HCT116 p53/
tumor cells). Of special note in the design of AM-8553 is theface-to-face, p-stacking interactions of the C5 aryl group with
His-96, the favorable conformational restrictions imposed by the
C3 methyl group and the improvements in the in vitro ADME prop-
erties (e.g., reduced liabilities in the hPXR, CYP3A4 and TDI assays)
obtained by the introduction of the secondary alcohol. Additional
structural studies have demonstrated that, despite the entropic
cost paid to order the ﬂexible N-terminal region of human hdm2,
piperidinone derivatives also engage residues 10 to 16, in particu-
lar Val-14 and Thr-16, in establishing interactions absent in the
endogenous p53/hdm2 contacts.26 Compound 12 inhibits, in a
dose-dependent manner, tumor growth in the SJSA-1 mouse xeno-
graft model when administered orally and causes tumor regression
(R = 27%) at the highest reported dose (200 mg/kg qd). No informa-
tion on the advancement of this series to clinical settings is avail-
able yet.
The 3-imidazolyl indole scaffold is another recent example of
the power of interactive molecular modeling in the design and
identiﬁcation of p53/hdm2 modulators. The central position of
the side-chain of Val-93 in the upper part of hdm2 was exploited
to design scaffolds that provided appropriate substitution vectors
to access the three binding pockets of the hdm2 cleft. Retrieving
and testing molecules based on this design concept, followed by
the structure-based design of some prototype molecules, allowed
the identiﬁcation of the 3-imidazolyl indole as an interesting scaf-
fold for further medicinal chemistry modiﬁcation.27 Interestingly,
the X-ray structure of compound 13 (Fig. 3; IC50 = 0.03 lM, bio-
chemical assay; IC50 = 7.3 lM antiproliferative activity, SJSA-1)
bound to hdm2 revealed an unexpected, although recurrent aro-
matic p-stacking interaction between the p-chloro-phenyl moiety
and the side-chain of His-96, and multiple water mediated hydro-
gen bond interactions between the carbonyl group of the amide
function of compound 13 and Lys-51, Phe-55 and Gln-59.
Another p53/hdm2 inhibitor with the code number MK-8242
(SCH900242) started Phase I clinical trials in December 2011. Nei-
ther the structure of this molecule nor its original source has been
disclosed yet.
2484 J.-C. Carry, C. Garcia-Echeverria / Bioorg. Med. Chem. Lett. 23 (2013) 2480–2485Parallel to the preceding efforts to design non-peptide like mol-
ecules, stapled peptides, which contain an all-hydrocarbon cross-
link to restore a-helical conformation, confer protease resistance
and favour cellular uptake,28 derived from the transactivation do-
main of p5329 have demonstrated unique hdm2 binding afﬁnities,
including dual inhibition towards hdmx. This protein is a close
homolog of hdm2 that potentiates the ubiquitin ligase activity of
hdm2 and blocks p53 transcriptional activity, but does not produce
p53 degradation. As in the case of hdm2, hdmx has been found to
be overexpressed in several cancers and, in the presence of this ge-
netic alteration, selective inhibition of the p53/hdm2 PPI may not
be sufﬁcient to fully activate p53. Interestingly, and due to minor
amino acid and conformational differences in the binding pockets
between hdm2 and hdmx,7,30 most of the preceding small-molec-
ular mass p53/hdm2 inhibitors tend to poorly inhibit the p53/
hdmx PPI and this has provided an impetus for the design of dual
hdm2 and hdmx PPI modulators. A representative example of a
dual inhibitor obtained with the stapled chemical strategy is
SAH-p53-8 (Ac-Gln-Ser-Gln-Gln-Thr-Phe-Xxx-Asn-Leu-Trp-Arg-
Leu-Leu-Yyy-Gln-Asn-NH2, in which the a-side chains of the Xxx
and Yyy residues are linked by (CH2)6–CH@CH–(CH2)3).29a,b This
peptide displayed signiﬁcant afﬁnity for hdmx (KD = 2.3 nM), sur-
passing that previously reported for hdm2 (KD = 55 nM). In cellular
settings, it was demonstrated that disruption of the p53/hdm2 PPI
in the presence of hdmx can limit p53-mediated cellular responses
by the formation of p53/hdmx complexes. When p53/hdmx com-
plex levels are elevated, inhibition of this PPI by SAH-p53-8 reacti-
vates the p53 pathway and induces cell death. Thus, cancer cell
sensitivity to pharmacologic inhibition of hdm2, hdmx or both tar-
gets could be determined by the respective levels and interactions
of wild-type p53 with hdm2 and hdmx.29a A stapled peptide may
be entering clinical trials in the near future, but no additional infor-
mation is in public domain yet.
Early inhibitors of the p53/hdm2 PPI have proven to be invalu-
able biological tools for improving our understanding of the p53
pathway and evaluate in preclinical settings the potential antitu-
mor activity and tolerability of this p53-based targeted therapy.
These studies have demonstrated that p53 wild-type status is nec-
essary but not sufﬁcient for antitumor activity, being ampliﬁed
MDM2 the best predictor for tumor cell sensitivity and induction
of apoptosis. Structure-based design approaches that build upon
the knowledge accumulated in the last few years have resulted
in the identiﬁcation of new compounds that are capable of modu-
lating the p53/hdm2 PPI in ways not previously possible. The in-
creased potency and pharmacological properties of these novel
inhibitors suggest that some of the promising ﬁndings observed
in in vitro and animal models may eventually come to be realized
in clinical settings. To this end, several p53/hdm2 inhibitors de-
rived from different chemical classes are currently undergoing
Phase I clinical trials for the treatment of a variety of solid tumors
and hematological malignancies. The medical beneﬁt and tolerabil-
ity of this ﬁrst generation of clinical candidates as single agents are
eagerly awaited. In this context, encouraging clinical activity in pa-
tients with leukemia treated with RG7112, including six acute
myeloid leukemia patients with complete response (16%) at the
maximum tolerated dose, has been reported at a recent meeting.31
Additional studies are needed to further establish the potential
therapeutic application of p53/hdm2 inhibitors, including further
elucidation of potential mechanism of resistance and combination
partners.
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